Method of inhibiting membrane-type matrix metalloproteinase

US6277061A · kind A · utility

Assignee

• The Research Foundation of the State University of New York · US

Inventors

• Lorne M. Golub · Smithtown, US
• Hsi-Ming Lee · Setauket, US
• Timo Sorsa · Helsinki, FI
• Olli Teronen · Helsinki, FI
• Tuula Salo · Haukipudas, FI

Key dates

• Filing date: Mar 31, 1998
• Grant date: Aug 21, 2001
• Expiry date: Mar 31, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is a method of inhibiting the activity of membrane-type matrix metalloproteinase (MT-MMP) in biological systems. Accordingly, the invention permits the treatment of medical conditions in mammals that are characterized by MT-MMP activity, and especially those conditions characterized by excessive MT-MMP activity. The method employs a tetracycline compound, preferably a non-antimicrobial tetracycline, and more preferably 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) or 6-.alpha.-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-8) to inhibit the MT-MMP activity.